A pilot study in prostate cancer and healthy volunteers revealed that ucfDNA might provide a more accurate alternative to serum prostate-specific antigen (PSA) for the early diagnosis of cancer [320]. This evidence concerns the gene KLK3 and prostate carcinoma.